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SUMMARY  25 
We investigated the impact of conjugate MenACWY immunization on carriage of Neisseria 26 
meningitidis in university students. Expansion of capsule-expressing isolates from the 2013-27 
strain of serogroup W:cc11, but not serogroup Y:cc23 isolates, suggests differential 28 
susceptibilities to vaccine-induced immunity. 29 
 30 
ABSTRACT  31 
Background. In the UK rising disease levels due to Neisseria meningitidis serogroup W 32 
clonal complex ST-11 (MenW:cc11) strains led to introduction of conjugate MenACWY 33 
vaccination for teenagers. We investigated the impact of immunization on carriage of 34 
targeted meningococci by whole genome sequencing of isolates recovered from a cohort of 35 
vaccinated university students.  36 
Methods. Strain designation data were extracted from whole genome sequence data. 37 
Genomes from carried and invasive MenW:cc11 were compared using a gene-by-gene 38 
approach. Serogrouping identified isolates expressing capsule antigens targeted by the 39 
vaccine. 40 
Results. Isolates with a W: P1.5,2: F1-1: ST-11 (cc11) designation, and belonging to the 41 
emerging ‘2013-strain’ of the South American-UK MenW:cc11 sub-lineage, were 42 
responsible for an increase in carried group W. A multifocal expansion was evident with 43 
close transmission networks extending beyond individual dormitories. Carried group Y 44 
isolates were predominantly from clonal complex 23, but showed significant heterogeneity 45 
and individual strain designations were only sporadically recovered. No shifts towards 46 
acapsulate phenotypes were detected in targeted meningococcal populations.  47 
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Conclusions. In a setting with high levels of conjugate MenACWY vaccination, expansion of 48 
capsule-expressing isolates from the 2013-strain of MenW:cc11, but not MenY:cc23 isolates, 49 
is indicative of differential susceptibilities to vaccine-induced immunity.  50 
 51 
Keywords: Neisseria meningitidis; whole genome sequencing; carriage; serogroup W; 52 
serogroup Y; epidemiology; vaccine  53 
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BACKGROUND 54 
Neisseria meningitidis is a commensal of the human oropharynx which can cause invasive 55 
meningococcal disease (IMD), principally characterized by sepsis and/or meningitis [1]. The 56 
majority of worldwide IMD is caused by isolates expressing the polysaccharide capsules that 57 
define serogroups A, B, C, W, Y, and X, whilst carriage isolates are frequently acapsulate 58 
due to the inactivation or absence of genes involved in capsule expression [2-4]. The 59 
incidence and contribution of different meningococcal lineages to the overall burden of IMD 60 
varies geographically, temporally and by age group, and can be further influenced by 61 
vaccination; capsule polysaccharide-based vaccines are available against serogroups A, C, W 62 
and Y, whilst protein-based vaccines are available against serogroup B isolates [5]. 63 
Monitoring trends in meningococcal populations requires discriminatory typing strategies. 64 
Whole genome sequence (WGS) analyses are now routine and enable differentiation of clonal 65 
complexes, sequence types and even highly-similar clones thereby facilitating detection of 66 
population level trends and individual transmission events [6].  67 
Over the last two decades, multiple countries have experienced increases in the 68 
incidence of IMD due to serogroup W (MenW) meningococci belonging to the sequence type 69 
11 clonal complex (cc11) [7-11]. Analysis of WGS data has indicated that most MenW:cc11 70 
isolates belong to cc11 lineage 11.1, with the global increases in MenW:cc11 disease 71 
resulting from emergence of two diversifying sub-lineages [12]. The Hajj sub-lineage 72 
comprises three main clusters of isolates (strains) corresponding to the Hajj outbreak of 2000 73 
onwards (Anglo-French Hajj strain), expansion of endemic disease in South Africa from 74 
2003 (endemic South African strain) and epidemics in sub-Saharan Africa (Burkina 75 
Faso/North African strain) [12]. The South American-UK sub-lineage comprises MenW:cc11 76 
that emerged in South America and subsequently spread to the UK and Europe [12]. This 77 
second lineage is associated with atypical clinical presentation, including gastrointestinal 78 
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symptoms, and a high case-fatality rate [13, 14]. Ongoing genomic surveillance has revealed 79 
further population structure details for the South American-UK MenW:cc11 sub-lineage such 80 
as the initial emergence of the ‘original UK’ strain in 2009, followed by subsequent 81 
emergence of the novel ‘2013-strain’ from this original UK strain [15]. 82 
The year-on-year increase in MenW:cc11 IMD cases in the UK since 2009 led to an 83 
emergency immunization program with meningococcal ACWY conjugate vaccine 84 
(MenACWY) being recommended to adolescents. This program included a phased catch-up 85 
campaign for individuals 14-18 years of age and began in August 2015 [16]. Older 86 
adolescents and young adults were targeted because these age groups exhibit higher 87 
oropharyngeal carriage rates than other age groups due to social factors [17, 18]. Particularly 88 
high carriage rates are evident in young adult populations residing in semi-closed 89 
communities (e.g. university students), where the potential for person-to-person transmission 90 
is especially high, and can lead to isolated clusters or outbreaks of meningococcal disease 91 
[19-22]. Hence, the MenACWY vaccination was also offered to new university entrants <25 92 
years of age. Furthermore, from previous experience with meningococcal group C conjugate 93 
vaccines, targeting adolescents and young adults could result in sustained decreases in 94 
disease incidence in all age groups by reducing the acquisition of meningococcal carriage 95 
(herd protection) [23].  96 
At the University of Nottingham (UoN), UK, a campus-based vaccination campaign 97 
targeting freshers in September 2015 increased MenACWY vaccination coverage in this 98 
specific student population from 31% to 71% [24]. To determine the effect of this vaccination 99 
campaign on meningococcal carriage, we conducted a cross-sectional study at the UoN, from 100 
September 2015 through to March 2016 [25]. The overall meningococcal carriage rate 101 
increased throughout the study in line with previous university-based carriage studies [26-102 
28]. No significant change in carriage of MenY organisms occurred, but we detected a rapid 103 
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and significant rise in carriage of MenW strains with PorB serotypes and porA and fHbp 104 
sequence types that matched alleles harbored by endemic UK MenW:cc11 invasive isolates 105 
[25]. Here we analyze whole genome data to define the specific MenW, MenY and non-106 
groupable lineages present in this student cohort, investigate the genetic relatedness of carried 107 
MenW:cc11 to contemporary invasive isolates, and consider the potential mechanisms by 108 
which vaccine-targeted isolates may escape immune responses elicited by vaccination with 109 
the MenACWY capsule-based conjugate vaccine.  110 
 111 
METHODS 112 
Carriage Isolates 113 
A total of 174 meningococcal isolates, all obtained from oropharyngeal carriers in 2015-16 at 114 
the UoN (East Midlands), United Kingdom [25] were included in the WGS analysis 115 
(Supplementary Table 1). Of these, 49 were MenW and 32 were MenY, together accounting 116 
for ca. 95% of MenW and MenY isolated during the carriage study [25]. A further 93 isolates 117 
were non-groupable (i.e. lacked ctrA or carried the capsule null locus), corresponding to ca. 118 
70% of non-groupable isolates obtained in the 2015-16 UoN study [25]. All isolates were 119 
chosen as known MenW, MenY or non-groupable organisms, based on PCR typing methods, 120 
without prior knowledge of their clonal complex. The Meningococcal Reference Unit, Public 121 
Health England, Manchester, UK performed serogrouping of MenY carriage isolates using 122 
dot-blot ELISA. Serogrouping of MenW carriage isolates was reported previously [25]. Chi-123 
square tests for significance were performed by using STATCALC (Epi Info version 7.2.0.1; 124 
Centers for Disease Control and Prevention, Atlanta, GA, USA). 125 
 126 
Genomic DNA Extraction, Sequencing, Assembly and Deposition 127 
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Meningococci were grown overnight on Columbia agar with chocolated horse blood (Thermo 128 
Fisher Scientific) at 37°C in an atmosphere of air plus 5% CO2. Genomic DNA was extracted 129 
using the Wizard Genomic DNA Purification Kit (Promega) according to manufacturer 130 
instructions. Index-tagged Illumina sequencing libraries were generated according to the 131 
manufacturer instructions, with an average insert size of 420 bp. These were multiplexed and 132 
sequenced on Illumina HiSeq 2500 machines to generate 125 bp paired-end sequences. An 133 
average of 2,773,968 reads per sample was generated, giving an average 125-fold coverage of 134 
the N. meningitidis genome. Short read sequences were trimmed with Trimmomatic v0.32 135 
[29] and assembled with SPAdes v3.9.0 [30] using the recommended parameters. Assemblies 136 
were deposited in, and subsequently automatically annotated by, the PubMLST.org/neisseria 137 
database which implements the Bacterial Isolate Genome Sequence (BIGSdb) platform [31]. 138 
Short-read sequences were also deposited in the European Nucleotide Archive (ENA) 139 
(Supplementary Table 1).  140 
 141 
Genomic Analyses 142 
Isolate capsular groups, multilocus sequence types, and porin A (PorA) and ferric 143 
enterochelin receptor (FetA) types were identified from whole genome data. For MenW:cc11 144 
carriage isolates, population-wide genomic analyses were undertaken using the BIGSdb 145 
Genome Comparator tool implemented within the PubMLST.org/neisseria database using the 146 
N. meningitidis cgMLST v1.0 core genome scheme (1605 loci) and default settings [31]. 147 
Output distance matrices (Nexus format) were used to generate NeighborNet networks using 148 
SplitsTree4 (v4.14.5). WGS data from MenW:cc11 carriage isolates were analyzed in 149 
conjunction with two other WGS data sets: (1) all UK MenW:cc11 invasive isolates for the 150 
epidemiological year 2015-16 (n=190) available via the Meningitis Research Foundation 151 
(MRF) Meningococcus Genome Library database 152 
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(http://pubmlst.org/perl/bigsdb/bigsdb.pl?db=pubmlst_neisseria_mrfgenomes; accessed July 153 
2017), and (2) a sub-set of the isolates previously used to define the sub-lineages/strains of 154 
lineage 11.1 by core genome analysis [12, 15] (n=60; Supplementary Table 2 and available 155 
via at https://pubmlst.org/bigsdb?db=pubmlst_neisseria_isolates; accessed July 2017).  156 
 157 
RESULTS 158 
Features of Sequenced Carriage Genomes 159 
After de novo assembly, the 125 bp paired Illumina reads from carriage isolates produced 160 
contiguous sequences between 2,018,737 to 2,155,185 bp in size, consistent with 161 
expectations for meningococcal genomes (Supplementary Table 1). Genome assemblies were 162 
automatically annotated in a ‘gene-by-gene’ approach using the BIGSdb platform and strain 163 
designation data extracted (Supplementary Table 1). For comparison, identical typing 164 
information was extracted from the WGS data of all invasive UK MenW (n=200) and MenY 165 
(n=104) isolates recovered during the same epidemiological year (2015-2016), and available 166 
via the MRF Meningococcus Genome Library database (Supplementary Tables 3 and 4, 167 
respectively).  168 
For MenW, isolates from cc11 predominated (95%), with the strain designation W: 169 
P1.5,2: F1-1: ST-11 (cc11) accounting for 88% of all MenW carriage, and 72% of all MenW 170 
invasive isolates, respectively (Table 1). Breakdown by isolation time-point confirmed that 171 
isolates with the W: P1.5,2: F1-1: ST-11 (cc11) designation were responsible for the increase 172 
in MenW carriage detected during the course of the 2015-16 carriage study (Table 1).  173 
For MenY, isolates from cc23 predominated (87%) (Table 2). Despite the overall 174 
number of MenY isolates being smaller than for MenW, a greater diversity was evident, with 175 
MenY populations encompassing a larger number of unique strain designations than MenW 176 
(39 and 26, respectively). Breakdown by isolation time-point revealed the sporadic recovery 177 
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of isolates from different MenY designations during the carriage study with only one 178 
designation, Y: P1.5-1,10-1: F4-1: ST-12176 (cc23), detected at all isolation time-points.  179 
 180 
WGS Analysis Resolves MenW:cc11 Carriage Isolates to the 2013-strain of the South 181 
American-UK Sub-lineage  182 
Higher resolution genealogical analysis of the MenW:cc11 isolates was realized by 183 
comparing the core genome sequences of carriage and invasive MenW:cc11 isolates (n=236). 184 
Identification of lineage 11.1 sub-lineages and strains was facilitated by inclusion of sixty 185 
additional isolates previously assigned by core genome analysis [12, 15]. Carriage and 186 
invasive MenW:cc11 isolates predominantly resolved to the 2013-strain cluster within the 187 
South American-UK sub-lineage (83% and 62%, respectively) (Figure 1 and Table 1). Core 188 
WGS analysis resolved isolates sharing the predominant W: P1.5,2: F1-1: ST-11 (cc11) 189 
designation to different 11.1 sub-lineages (i.e. South American-UK and Hajj, respectively), 190 
and within the South American-UK sub-lineage, into different strain types (Table 1). 191 
Isolation time-point analysis revealed that although isolates with the W: P1.5,2: F1-1: ST-11 192 
(cc11) designation from the original and South American strains were recovered at multiple 193 
time-points, the increase in MenW carriage was almost entirely due to W: P1.5,2: F1-1: ST-194 
11 (cc11) isolates from the 2013-strain (2, 16 and 19 isolates in September, November and 195 
March, respectively) (Table 1).  196 
To visualize the relationships among isolates from the 2013-strain type more clearly, 197 
a NeighborNet network was generated from a separate core genome comparison of the 198 
carried (n=38) and invasive (n=117) 2013-strain isolates, with color-coding of nodes 199 
detailing provenance. This revealed a multifocal expansion of carriage isolates, with 97% of 200 
the November 2015 and March 2016 isolates resolved to five clusters (Figure 2). Isolates 201 
within each cluster differed at only a small number of core genome loci suggesting multiple 202 
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close transmission networks. The MenACWY coverage rate for clusters A-E ranged from 203 
57%-83% confirming that transmission within all five networks was not restricted to 204 
unvaccinated individuals (Figure 2). As sampling of students in November 2015 and March 205 
2016 occurred in five dormitories [25], we examined whether 2013-strain isolate clusters 206 
correlated with dormitory of isolation. Each cluster contained isolates recovered from at least 207 
three different sampling sites suggesting that transmission networks extended beyond 208 
individual dormitories (Supplementary Figure 1).  209 
 210 
Effect of MenACWY Vaccination on Group W and Y Capsule Expression 211 
Mucosal immune responses elicited by MenACWY vaccination have the potential to 212 
influence capsule expression in target serogroups. We determined whether circulating MenW 213 
and MenY shifted towards a non-serogroupable (i.e. acapsulate) phenotype, however no 214 
significant changes were detected in the proportions of MenW:cc11 original strain, 215 
MenW:cc11 2013-strain, other MenW, MenY:cc23 or other MenY isolates expressing 216 
capsule between time-points (Table 3). Likewise the specific incidences of encapsulated or 217 
acapsulate MenY:cc23 (or other MenY) in the population showed no significant changes 218 
during the study. For MenW, the increasing incidence of carriage was driven by significant 219 
increases in both encapsulated and non-capsulated MenW:cc11 2013-strain isolates (Table 3). 220 
Notably 85% of MenW:cc11 2013-strain isolates recovered in March 2016 expressed 221 
capsule, with 82% of individuals carrying the encapsulated 2013-strain isolates at this time-222 
point having received MenACWY vaccine before or during September 2015 (Table 3).  223 
 224 
Absence of Isolates From cc11 and cc23 Amongst Non-groupable Carriage Isolates 225 
We obtained WGS data for an additional 93 non-groupable (i.e. isolates lacking ctrA or 226 
carrying the capsule null locus) carriage isolates. Extracted strain designations showed that 227 
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isolates from cc198 were most prevalent (35%), followed by cc53 (26%) and cc865 (9%). 228 
Importantly, no isolates from the relevant IMD-associated MenW and MenY clonal 229 
complexes (cc11 and cc23, respectively) were detected, suggesting that deletion of part, or 230 
all, of the capsule locus by isolates of these lineages to avoid vaccine-induced immune 231 
responses had not occurred. 232 
 233 
DISCUSSION 234 
Since its appearance in 2013, cases of IMD in the UK due to the 2013-strain of the South 235 
American-UK sub-lineage of MenW:cc11 have approximately doubled year-on-year, while 236 
expansion of the original strain has slowed [15]. Here we show that the increase in carried 237 
MenW detected at a UK university during 2015-16 [25] was also due to expansion of the 238 
2013-strain, a finding that was reliant on the ability of core genome analysis to resolve 239 
apparently indistinguishable isolates sharing the designation W: P1.5,2: F1-1: ST-11 (cc11). 240 
Importantly, both the original and the 2013-strain MenW:cc11 strains were carried by in-241 
coming students, yet only the 2013-strain expanded. This suggests differences in strain 242 
transmissibility and/or host susceptibility to oropharyngeal carriage in this population. 243 
Further studies may indicate whether the differential expansion relates to the previously 244 
determined four point mutations and three distinct recombination events which distinguish 245 
the strains [15] or other, as yet undetermined genetic differences. As well as being a highly 246 
virulent strain with a notable tendency for atypical clinical presentation and a high case-247 
fatality rate [13-15], our findings suggest that the 2013-strain may result in relatively high 248 
levels of carriage in semi-closed communities of young adults, a phenomenon not previously 249 
detected for the original strain or MenC:cc11 [32]. Such settings may act as a reservoir for 250 
the 2013-strain, leading to case-clusters or outbreaks of disease in susceptible students [22] 251 
and onward transmission to unvaccinated cohorts in the wider population.  252 
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Of concern, the expansion of the 2013-strain occurred in the context of a student 253 
population which had, for the most part, received conjugate MenACWY vaccination. This 254 
vaccination had been introduced specifically because of the rapid and sustained increase in 255 
MenW:cc11 IMD in the UK [16] and led to a reduction in MenW cases in the first vaccine-256 
targeted UK cohort who entered university [33]. Vaccination was targeted at older adolescent 257 
and young adults in order to provide direct protection to these age groups but also to generate 258 
indirect ‘herd’ protection as observed for the MenC and MenA monovalent conjugate 259 
vaccines where high vaccine coverage in these age groups reduced serogroup-specific 260 
carriage [32, 34]. Evidence supporting a comparable impact of quadrivalent MenACWY 261 
conjugate vaccines on carriage is currently lacking, albeit two studies in different populations 262 
have shown MenACWY vaccination elicited a modest impact on meningococcal carriage in 263 
vaccinated individuals [35, 36]. In a study involving UK university students, carriage rates of 264 
serogroup Y and combined serogroups CWY were significantly lower two months after 265 
vaccination with MenACWY [35], whilst in Polish soldiers meningococcal carriage was 266 
9.6% in unvaccinated individuals and 1.2% in individuals vaccinated 1-3 years previously 267 
with MenACWY vaccine [36]. Of note, however, prior to vaccination serogroup Y carriage 268 
predominated over serogroup C and W carriage in the former study, and serogroup Y and C 269 
carriage were dominant in the latter study, suggesting that the observed effects of 270 
MenACWY vaccination on carriage were predominantly due to reductions in carriage of 271 
serogroup Y, or Y and C strains, respectively. 272 
Our data suggest that the MenW component of conjugate MenACWY vaccines does 273 
not impact significantly on MenW carriage or does so at a lower level as compared to the 274 
MenY component. Thus the sporadic and limited recovery of MenY designations, 275 
particularly cc23 isolates, during this carriage study, is indicative of an absence of 276 
transmission events in this cohort. This is in marked contrast to the findings of previous 277 
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studies of meningococcal carriage in university students, where MenY strains of similar 278 
clonal complexes expanded significantly and persisted in unvaccinated populations [27, 28, 279 
37, 38]. Furthermore, the finding that the vast majority of the isolates of the 2013-strain were 280 
expressing the W capsule at the March time-point is consistent with the hypothesis that the 281 
capsular polysaccharide antigen was not under significant selective pressure from the 282 
introduction of the MenACWY vaccine in this population. In contrast, in a study examining 283 
the impact of MenC monovalent conjugate vaccination on carriage, Maiden and colleagues 284 
detected a significant reduction in both the prevalence of MenC:cc11 and in the proportion of 285 
recovered MenC:cc11 isolates expressing capsule (81% in 1999 and 43% in 2001, 286 
respectively) [32]. A caveat is that the majority of MenW:cc11 transmission events may have 287 
occurred in students immunized in September and during the early part of the academic year, 288 
a period known to coincide with rapid meningococcal transmission and carriage acquisition 289 
in first-year students [19]. Thus, vaccine-elicited immune responses may have developed too 290 
slowly to impact on the acquisition of MenW:cc11 but not MenY:cc23 strains. Vaccinating 291 
adolescents earlier and achieving higher coverage (i.e. the aim of the routine adolescent 292 
schools program where preliminary coverage was >77% [39]) may reduce MenW:cc11 293 
acquisition and carriage and eventually lead to population-wide herd immunity. Ongoing 294 
surveillance will be needed to establish whether MenW:cc11 carriage declines as these 295 
cohorts enter the university population.  296 
Our cross-sectional study precluded comment on the duration of carriage of the 2013-297 
MenW:cc11 strains in individuals. However prolonged carriage of these strains in 298 
MenACWY-vaccinated individuals could be critically important due to the potential for 299 
spread to non-vaccinated individuals in the population. A longitudinal study is required to 300 
determine whether there are differences in MenW/Y carriage duration in vaccinated 301 
individuals as implied by our current study. Additionally, an examination of the impact of 302 
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MenACWY vaccination on the density of meningococcal carriage is required. In a recent 303 
study, Finn and colleagues utilized quantitative PCR to assess the density of meningococcal 304 
carriage and observed temporal and individual variation of several orders of magnitude [40]. 305 
Our study cannot exclude the possibility of an effect of MenACWY immunization on 306 
carriage density in vaccinated as compared to unvaccinated individuals.  307 
In conclusion, we show that the hyper-virulent 2013-strain of the South American-UK 308 
MenW:cc11 sub-lineage was responsible for an increase in group W carriage reported at a 309 
UK university. Analysis of WGS data revealed close transmission networks that extended 310 
beyond individual dormitories. Furthermore, on-campus MenACWY vaccination did not 311 
prevent expansion of capsule-expressing isolates from the 2013-strain of MenW:cc11. These 312 
findings are important for predicting the rate of development of population-wide herd 313 
immunity in the UK and for protecting older unvaccinated cohorts. In the period January 314 
through March 2017, there were 51 cases of MenW IMD in individuals aged >45 years in 315 
England [39]. Finally, further studies are required to determine whether carriage of the 2013-316 
strain is increasing in the wider population of older adolescents and young adults in UK, and 317 
in other countries where there are similar increases in IMD due to this emerging strain.  318 
 319 
POTENTIAL CONFLICTS OF INTEREST 320 
N. J. O. and L. R. G. have no potential conflicts. J. P. has been a consultant to Specific 321 
Technologies and has received research funding from Pfizer. C. D. B. collaborates with 322 
GlaxoSmithKline. D. P. J. T. has received support from Novartis Vaccines (now a part of 323 
GlaxoSmithKline), Sanofi Pasteur and GlaxoSmithKline, including honoraria, grants and 324 
travel assistance for conferences. 325 
 326 
FUNDING 327 
15 
 
This work was supported by the University of Nottingham, the Medical Research Council, 328 
UK (grant number MR/M020193/1 to C. D. B.) and the Wellcome Trust (grant number 329 
098051). The funders had no involvement in the design of the study or the preparation of the 330 
article. 331 
 332 
CORRESPONDING AUTHOR CONTACT INFORMATION 333 
Neil Oldfield, Centre for Biomolecular Sciences, University of Nottingham, Nottingham 334 
NG7 2RD, UK. E-mail: neil.oldfield@nottingham.ac.uk. Tel: (+44) 115748 6122. Fax: (+44) 335 
115846 8002. 336 
 337 
ACKNOWLEDGMENTS 338 
We thank Ray Borrow, Steve Gray and Anthony Carr from the Meningococcal Reference 339 
Unit, Public Health England, Manchester, UK, for serogrouping meningococcal isolates. This 340 
publication made use of the Meningitis Research Foundation Meningococcus Genome 341 
Library (http://www.meningitis.org/research/genome) developed by Public Health England, 342 
the Wellcome Trust Sanger Institute and the University of Oxford as a collaboration. The 343 
project is funded by Meningitis Research Foundation. 344 
 345 
REFERENCES 346 
1. Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human 347 
bacterium Neisseria meningitidis. Vaccine 2009; 27:B71-7. 348 
2. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. 349 
Vaccine 2009; 27:B51-B63. 350 
3. Caugant DA, Maiden MCJ. Meningococcal carriage and disease - population biology and 351 
evolution. Vaccine 2009; 27:B64-B70. 352 
16 
 
4. Weber MV, Claus H, Maiden MC, Frosch M, Vogel U. Genetic mechanisms for loss of 353 
encapsulation in polysialyltransferase-gene-positive meningococci isolated from healthy 354 
carriers. Int J Med Microbiol 2006; 296:475-84. 355 
5. Crum-Cianflone N, Sullivan E. Meningococcal Vaccinations. Infect Dis Ther 2016; 5:89-356 
112. 357 
6. Maiden MC, Jansen van Rensburg MJ, Bray JE, et al. MLST revisited: the gene-by-gene 358 
approach to bacterial genomics. Nat Rev Microbiol 2013; 11:728-36. 359 
7. von Gottberg A, du Plessis M, Cohen C, et al. Emergence of endemic serogroup W135 360 
meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis 361 
2008; 46:377 - 86. 362 
8. Abad R, Lopez EL, Debbag R, Vazquez JA. Serogroup W meningococcal disease: global 363 
spread and current affect on the Southern Cone in Latin America. Epidemiol Infect 2014; 364 
142:2461-70. 365 
9. Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis 366 
capsular group W sequence type 11 complex associated with severe invasive disease in 367 
England and Wales. Clin Infect Dis 2015; 60:578-85. 368 
10. Lahra MM, Enriquez RP, National Neisseria N. Australian Meningococcal Surveillance 369 
Programme annual report, 2015. Commun Dis Intell Q Rep 2016; 40:E503-E11. 370 
11. Mustapha MM, Marsh JW, Harrison LH. Global epidemiology of capsular group W 371 
meningococcal disease (1970-2015): Multifocal emergence and persistence of hypervirulent 372 
sequence type (ST)-11 clonal complex. Vaccine 2016; 34:1515-23. 373 
12. Lucidarme J, Hill DM, Bratcher HB, et al. Genomic resolution of an aggressive, 374 
widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect 375 
2015; 71:544-52. 376 
17 
 
13. Campbell H, Parikh SR, Borrow R, Kaczmarski E, Ramsay ME, Ladhani SN. 377 
Presentation with gastrointestinal symptoms and high case fatality associated with group W 378 
meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016. Euro 379 
Surveill 2016; 21:30175. 380 
14. Moreno G, Lopez D, Vergara N, Gallegos D, Advis MF, Loayza S. [Clinical 381 
characterization of cases with meningococcal disease by W135 group in Chile, 2012]. Rev 382 
Chilena Infectol 2013; 30:350-60. 383 
15. Lucidarme J, Scott KJ, Ure R, et al. An international invasive meningococcal disease 384 
outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, 385 
July to August 2015. Euro Surveill 2016; 21:30395. 386 
16. Campbell H, Saliba V, Borrow R, Ramsay M, Ladhani SN. Targeted vaccination of 387 
teenagers following continued rapid endemic expansion of a single meningococcal group W 388 
clone (sequence type 11 clonal complex), United Kingdom 2015. Euro Surveill 2015; 389 
20:21188. 390 
17. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by 391 
age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-61. 392 
18. Soriano-Gabarro M, Wolter J, Hogea C, Vyse A. Carriage of Neisseria meningitidis in 393 
Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther 2011; 394 
9:761-74. 395 
19. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, et al. Changing carriage rate of Neisseria 396 
meningitidis among university students during the first week of term: cross sectional study. 397 
BMJ 2000; 320:846-9. 398 
20. Biswas HH, Han GS, Wendorf K, et al. Notes from the field: outbreak of serogroup B 399 
meningococcal disease at a university - California, 2016. MMWR Morb Mortal Wkly Rep 400 
2016; 65:520-1. 401 
18 
 
21. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease 402 
outbreak and carriage evaluation at a college - Rhode Island, 2015. MMWR Morb Mortal 403 
Wkly Rep 2015; 64:606-7. 404 
22. Bassi C, Taha M, Merle C, et al. A cluster of invasive meningococcal disease (IMD) 405 
caused by Neisseria meningitidis serogroup W among university students, France, February 406 
to May 2017. Euro Surveill 2017; 22:30574. 407 
23. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned 408 
from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8:851-61. 409 
24. Turner DP, Oldfield NJ, Bayliss CD. University vaccine campaign increases 410 
meningococcal ACWY vaccine coverage. Public Health 2017; 145:1-3. 411 
25. Oldfield NJ, Cayrou C, AlJannat MAK, et al. Rise in group W meningococcal carriage in 412 
university students, United Kingdom. Emerg Infect Dis 2017; 23:1009-11. 413 
26. Ala'Aldeen DAA, Neal KR, Ait-Tahar K, et al. Dynamics of meningococcal long-term 414 
carriage among university students and their implications for mass vaccination. J Clin 415 
Microbiol 2000; 38:2311-6. 416 
27. Bidmos FA, Neal KR, Oldfield NJ, Turner DPJ, Ala’Aldeen DAA, Bayliss CD. Rapid 417 
clonal expansion, persistence and clonal replacement of meningococcal carriage isolates in a 418 
2008 university student cohort. J Clin Microbiol 2011; 49:506-12. 419 
28. Ala’Aldeen DAA, Oldfield NJ, Bidmos FA, et al. Carriage of meningococci by university 420 
students, United Kingdom. Emerg Infect Dis 2011; 17:1761-3. 421 
29. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence 422 
data. Bioinformatics 2014; 30:2114-20. 423 
30. Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly algorithm and 424 
its applications to single-cell sequencing. J Comput Biol 2012; 19:455-77. 425 
19 
 
31. Bratcher HB, Corton C, Jolley KA, Parkhill J, Maiden MC. A gene-by-gene population 426 
genomics platform: de novo assembly, annotation and genealogical analysis of 108 427 
representative Neisseria meningitidis genomes. BMC Genomics 2014; 15:1138. 428 
32. Maiden MCJ, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C 429 
conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-43. 430 
33. Campbell H, Edelstein M, Andrews N, Borrow R, Ramsay M, Ladhani S. Emergency 431 
meningococcal ACWY vaccination program for teenagers to control group W meningococcal 432 
disease, England, 2015-2016. Emerg Infect Dis 2017; 23:1184-7. 433 
34. Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the serogroup A meningococcal 434 
conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013; 435 
56:354-63. 436 
35. Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY 437 
glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an 438 
observer-blind, phase 3 randomised clinical trial. Lancet 2014; 384:2123-31. 439 
36. Korzeniewski K, Skoczynska A, Guzek A, et al. Effectiveness of immunoprophylaxis in 440 
suppressing carriage of Neisseria meningitidis in the military environment. Adv Exp Med 441 
Biol 2015; 836:19-28. 442 
37. Oldfield NJ, Harrison OB, Bayliss CD, Maiden MCJ, Ala' Aldeen DAA, Turner DPJ. 443 
Genomic analysis of serogroup Y Neisseria meningitidis isolates reveals extensive 444 
similarities between carriage and disease-associated organisms. J Infect Dis 2016; 213:1777-445 
85. 446 
38. Deasy AM, Guccione E, Dale AP, et al. Nasal inoculation of the commensal Neisseria 447 
lactamica inhibits carriage of Neisseria meningitidis by young adults: a controlled human 448 
infection study. Clin Infect Dis 2015; 60:1512-20. 449 
39. Public Health England. Health Protection Report 2017. 11 (23). 450 
20 
 
40. Finn A, Morales-Aza B, Sikora P, et al. Density distribution of pharyngeal carriage of 451 
meningococcus in healthy young adults: new approaches to studying the epidemiology of 452 
colonization and vaccine indirect effects. Pediatr Infect Dis J 2016; 35:1080-5.  453 
21 
 
FIGURE LEGENDS 454 
Figure 1. NeighborNet network based on the comparison of 1605 core genome loci amongst 455 
lineage 11.1 genomes (n=296). Three sets of isolates were included: (1) MenW:cc11 UK 456 
carriage isolates (n=46); (2) MenW:cc11 UK 2015-16 invasive isolates (n=190), and (3) 457 
previously assigned MenW:cc11 isolates (n=60). Thirty eight carriage isolates localized to 458 
the 2013-strain of the South American-UK sub-lineage, whilst four carriage isolates resolved 459 
to each of the original and South American strain clusters, respectively. Thirty previously 460 
assigned isolates and two MenW:cc11 UK 2015-16 invasive isolates resolved to the Hajj sub-461 
lineage (‘to Hajj sub-lineage’). Nodes are color coded: carriage isolates in red; invasive 462 
isolates in black; previously assigned isolates in blue. Scale bar = number of allelic 463 
differences. 464 
 465 
Figure 2. NeighborNet network based on the comparison of 1605 core genome loci amongst 466 
2013-strain isolates. Two sets of isolates were included: (1) 2013-strain MenW:cc11 UK 467 
carriage isolates (n=38) and (2) 2013-strain MenW:cc11 UK 2015-16 invasive isolates 468 
(n=117). Nodes are color coded: invasive isolates in black; September 2015 carriage isolates 469 
in red; November 2015 carriage isolates in green; March 2016 carriage isolates in blue. 97% 470 
of the November 2015 and March 2016 carriage isolates resolved to five clusters (labelled A-471 
E), with isolates within each cluster being highly similar (cg diff. = core genome differences). 472 
82%, 60%, 83%, 57% and 80% of carriers harboring the isolates in clusters A-E, 473 
respectively, had received MenACWY vaccine before or during registration (September 474 
2015). Scale bar = number of allelic differences. 475 
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Table 1. Breakdown of MenW Carriage and Invasive Isolates by Strain Designation, 11.1 Sub-lineage and Strain Type, and Isolation 476 
Time-Point 477 
Strain designationa 11.1 sub-lineageb Strain typeb 
Isolation time-point 
Total 
carriage 
(n=49) 
Invasive 
2015-16 
(n=200) 
Total carriage 
and invasive 
(n=249) 
Sep 
2015 
(n=5) 
Nov 
2015 
(n=20) 
Mar 
2016 
(n=24) 
W: P1.5,2: F1-1: ST-11 (cc11) South American-UK 2013 2 16 19 37 101 138 
  Original 2 0 0 2 40 42 
  South American 0 2 2 4 0 4 
 Hajj  ND 0 0 0 0 2 2 
         
W: P1.5,2: F1-1: ST-ND (cc11) South American-UK  2013 0 0 1 1 15 16 
  Original 0 0 0 0 6 6 
         
W: P1.5,2: F1-1: ST-10651 (cc11) South American-UK  Original 1 1 0 2 8 10 
         
W: P1.5,2: F1-146: ST-11 (cc11) South American-UK  Original 0 0 0 0 8 8 
         
W: P1.5,2: F1-146: ST-ND (cc11) South American-UK  Original 0 0 0 0 2 2 
         
Other cc11c South American-UK  2013 0 0 0 0 1 1 
  Original 0 0 0 0 7 7 
         
Other non-cc11d NA NA 0 1 2 3 10 13 
   478 
a Derived from genome sequence data 479 
b As assigned by core genome analysis (shown in Figure 1) 480 
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c Includes all cc11 strain designations occurring only once 481 
d Includes all non-cc11 strain designations  482 
ND = not determined; NA = not applicable  483 
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Table 2. Frequency of Strain Designations in the MenY Carriage and Invasive Collections  484 
Clonal complexa Strain designationa 
Isolation time-point Total 
carriage 
(n=32) 
Invasive 
2015-16 
(n=104) 
Total carriage 
and invasive 
(n=136) 
Sep 2015 
(n=14) 
Nov 2015 
(n=8) 
Mar 2016 
(n=10) 
cc23 Y: P1.5-1,10-1: F4-1: ST-1655 (cc23) 4 0 1 5 40 45 
 Y: P1.5-1,10-4: F4-1: ST-23 (cc23) 2 3 0 5 7 12 
 Y: P1.5-1,10-1: F4-1: ST-ND (cc23) 0 0 0 0 12 12 
 Y: P1.5-2,10-1: F4-1: ST-23 (cc23) 0 0 0 0 9 9 
 Y: P1.5-1,10-4: F4-1: ST-1655 (cc23) 1 0 2 3 4 7 
 Y: P1.5-1,10-1: F4-1: ST-12176 (cc23) 1 1 2 4 1 5 
 Y: P1.5-1,10-4: F4-1: ST-ND (cc23) 0 0 0 0 5 5 
 Y: P1.5-1,10-1: F4-1: ST-11754 (cc23) 0 0 0 0 3 3 
 Y: P1.5-1,10-10: F4-1: ST-1655 (cc23) 2 0 0 2 0 2 
 Y: P1.5-1,10-8: F4-1: ST-1655 (cc23) 1 0 1 2 0 2 
 Otherb 1 2 1 4 12 16 
        
Non-cc23 Y: P1.21,16: F3-7: ST-1466 (cc174) 0 0 0 0 3 3 
 Y: P1.18-7,9: F3-9: ST-ND (cc103) 0 1 1 2 0 2 
 Y: P1.5-1,10-4: F3-4: ST-10730 (cc167) 0 0 0 0 2 2 
 Y: P1.5-1,10-22: F5-1: ST-ND (cc22) 0 0 0 0 2 2 
 Otherc 2 1 2 5 4 9 
  485 
a Derived from genome sequence data 486 
b Includes all cc23 strain designations occurring only once 487 
c Includes all non-cc23 strain designations occurring only once  488 
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Table 3. Prevalence of Capsule-Expressing and Acapsulate MenW and MenY Genogroups by Isolation Time-Point 489 
Isolation 
time-point 
(no. of 
participants) 
Capsule 
expression 
status 
Genogroup 
MenW:cc11 2013-
strain only 
MenW:cc11 original 
strain only 
Other MenW MenY:cc23 only Other MenYa 
No. (%) 
of 
isolates 
% of 
participants 
(95% CI) 
No. (%) 
of 
isolates 
% of 
participants 
(95% CI) 
No. (%) 
of 
isolates 
% of 
participants 
(95% CI) 
No. (%) 
of 
isolates 
% of 
participants 
(95% CI) 
No. (%) 
of 
isolates 
% of 
participants 
(95% CI) 
September 
(n=769) 
On 0 0 2 
(67) 
0.3 
(0.0-0.6) 
0 0 8 
(67) 
1.0 
(0.3-1.8) 
1 
(50) 
0.1 
(0.0-0.4) 
Off 2 
(100) 
0.3 
(0.0-0.6) 
1 
(33) 
0.1 
(0.0-0.4) 
0 0 4 
(33) 
0.5 
(0.0-0.1) 
1 
(50) 
0.1 
(0.0-0.4) 
            
November 
(n=353) 
On 9b 
(56) 
2.5 
(0.9-4.2)*** 
1 
(100) 
0.3 
(0.0-0.8) 
2 
(67) 
0.6 
(0.0-1.3) 
1 
(17) 
0.3 
(0.0-0.8) 
2 
(100) 
0.6 
(0.0-1.3) 
Off 7c 
(44) 
2.0 
(0.5-3.4)** 
0 0 1 
(33) 
0.3 
(0.0-0.8) 
5 
(83) 
1.4 
(0.2-2.6) 
0 0 
            
March 
(n=268) 
On 17d 
(85) 
6.3 
(3.4-9.3)* 
0 0 0 0 4 
(57) 
1.5 
(0.0-2.9) 
0 0 
Off 3e 
(15) 
1.1 
(0.0-2.4) 
0 0 4 
(100) 
1.5 
(0.0-2.9) 
3 
(43) 
1.1 
(0.0-2.4) 
2 
(100) 
0.7 
(0.0-1.8) 
Asterisks indicate a statistically significant difference compared to prevalence at the preceding time-point (*p<0.05; **p<0.01, ***p<0.0001) 490 
a Serogrouping data unavailable for one MenY:cc103 isolate from March 2016 491 
b Of these, 5/9 (56%) had received MenACWY vaccine before or during registration (September 2015) 492 
c Of these, 6/7 (86%) had received MenACWY vaccine before or during registration (September 2015)  493 
d Of these, 14/17 (82%) had received MenACWY vaccine before or during registration (September 2015)  494 
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e Of these, 3/3 (100%) had received MenACWY vaccine before or during registration (September 2015) 495 
10.0
South American strain
Original strain
2013-strain
To Hajj sub-lineage
E (n=5)
3-14 cg diff.
D (n=7)
7-12 cg diff.C (n=6)
6-31 cg diff.
B (n=5)
5-11 cg diff.
A (n=11)
9-42 cg diff.
10.0
